- Home
- DHY vs CRDF Comparison
DHY vs CRDF Comparison
Compare DHY & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHY
- CRDF
- Stock Information
- Founded
- DHY 1998
- CRDF 1999
- Country
- DHY United States
- CRDF United States
- Employees
- DHY N/A
- CRDF N/A
- Industry
- DHY Finance/Investors Services
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DHY Finance
- CRDF Health Care
- Exchange
- DHY Nasdaq
- CRDF Nasdaq
- Market Cap
- DHY 224.6M
- CRDF 240.2M
- IPO Year
- DHY N/A
- CRDF N/A
- Fundamental
- Price
- DHY $2.13
- CRDF $3.52
- Analyst Decision
- DHY
- CRDF Strong Buy
- Analyst Count
- DHY 0
- CRDF 3
- Target Price
- DHY N/A
- CRDF $10.33
- AVG Volume (30 Days)
- DHY 569.1K
- CRDF 1.2M
- Earning Date
- DHY 01-01-0001
- CRDF 02-27-2025
- Dividend Yield
- DHY 9.10%
- CRDF N/A
- EPS Growth
- DHY N/A
- CRDF N/A
- EPS
- DHY N/A
- CRDF N/A
- Revenue
- DHY N/A
- CRDF $688,000.00
- Revenue This Year
- DHY N/A
- CRDF $25.03
- Revenue Next Year
- DHY N/A
- CRDF N/A
- P/E Ratio
- DHY N/A
- CRDF N/A
- Revenue Growth
- DHY N/A
- CRDF 49.57
- 52 Week Low
- DHY $1.77
- CRDF $1.44
- 52 Week High
- DHY $2.08
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- DHY 43.29
- CRDF 46.40
- Support Level
- DHY $2.10
- CRDF $3.33
- Resistance Level
- DHY $2.19
- CRDF $4.89
- Average True Range (ATR)
- DHY 0.03
- CRDF 0.29
- MACD
- DHY -0.00
- CRDF -0.13
- Stochastic Oscillator
- DHY 37.50
- CRDF 14.91
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company with the objective to seek high current income and capital appreciation as a secondary objective.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").